GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » RadNet Inc (NAS:RDNT) » Definitions » Forward PE Ratio
中文

RadNet (RadNet) Forward PE Ratio

: 0.00 (As of Today)
View and export this data going back to 1997. Start your Free Trial

RadNet's Forward PE Ratio for today is 0.00.

RadNet's PE Ratio without NRI for today is 157.74.

RadNet's PE Ratio for today is 0.00.


RadNet Forward PE Ratio Historical Data

The historical data trend for RadNet's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RadNet Annual Data
Trend 2015-12 2016-12 2017-02 2018-12 2019-08
Forward PE Ratio
11.04 17.42 16.75 18.80 36.23

RadNet Quarterly Data
2015-12 2016-12 2018-06 2018-09 2018-12 2019-03
Forward PE Ratio 11.04 17.42 39.53 25.06 18.80 22.52

Competitive Comparison

For the Diagnostics & Research subindustry, RadNet's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RadNet Forward PE Ratio Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, RadNet's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where RadNet's Forward PE Ratio falls into.



RadNet Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


RadNet  (NAS:RDNT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


RadNet Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of RadNet's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


RadNet (RadNet) Business Description

Traded in Other Exchanges
Address
1510 Cotner Avenue, Los Angeles, CA, USA, 90025
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
Executives
Michael N Murdock officer: Executive Vice President 3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 752012776
Christine Nayoma Gordon director 3081 PANAMA AVE., CARMICHAEL CA 95608
Gregory Sorensen director, officer: EVP Chief Science Officer C/O DFB HEALTHCARE ACQUISITIONS CORP, 780 THIRD AVENUE, NEW YORK NY 10017
Norman R Hames director, officer: Vice President
Stephen M Forthuber officer: Executive Vice President 3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 75201-2776
Ruth Louisa Villigerwilson director, officer: Senior Vice President 3700 WALNUT AVENUE, LONG BEACH CA 90801
David L Swartz director 1510 COTNER AVENUE, LOS ANGELES CA 90025
Gregory E. Spurlock director 4116 E. NORTHRIDGE CIRCLE, MESA AZ 85215-9807
John V Crues director 1510 COTNER AVE, LOS ANGELES CA 90025
Lawrence L Levitt director 2934 1/2 BEVERLY GLEN CIRCLE #325, LOS ANGELES CA 90077
Ranjan Jayanathan officer: Chief Information Officer 13388 HUNT RIDGE ROAD, ELLICOTT CITY MD 21042
Laura Pastre Jacobs director 10154 BRIDLEVALE DRIVE, LOS ANGELES CA 90064
Karen B. Kaplan Survivor's Trust other: Indirect owner 10776 WILSHIRE BLVD/, LOS ANGELES CA 90024-6447
David Jeffrey Katz officer: EVP and General Counsel 1510 COTNER AVE, LOS ANGELES CA 90025
Sherman Michael L Md director